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Abstract
Background
Fatty liver is a major cause of obesity-related morbidity and mortality. The aim of this study
was to identify early metabolic alterations associated with liver fat accumulation in 50- to 55-
year-old men (n = 49) and women (n = 52) with and without NAFLD.
Methods
Hepatic fat content was measured using proton magnetic resonance spectroscopy (1H
MRS). Serum samples were analyzed using a nuclear magnetic resonance (NMR) metabo-
lomics platform. Global gene expression profiles of adipose tissues and skeletal muscle
were analyzed using Affymetrix microarrays and quantitative PCR. Muscle protein expres-
sion was analyzed by Western blot.
Results
Increased branched-chain amino acid (BCAA), aromatic amino acid (AAA) and orosomu-
coid were associated with liver fat accumulation already in its early stage, independent of
sex, obesity or insulin resistance (p<0.05 for all). Significant down-regulation of BCAA
catabolism and fatty acid and energy metabolism was observed in the adipose tissue of the
NAFLD group (p<0.001for all), whereas no aberrant gene expression in the skeletal muscle
was found. Reduced BCAA catabolic activity was inversely associated with serum BCAA
and liver fat content (p<0.05 for all).
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Conclusions
Liver fat accumulation, already in its early stage, is associated with increased serum
branched-chain and aromatic amino acids. The observed associations of decreased BCAA
catabolism activity, mitochondrial energy metabolism and serum BCAA concentration with
liver fat content suggest that adipose tissue dysfunction may have a key role in the systemic
nature of NAFLD pathogenesis.
Introduction
The prevalence of non-alcoholic fatty liver (NAFLD) is on the rise, currently affecting up to
30% of the adult population and an increasing number of children in the developed countries
[1]. In the early phase, NAFLD is asymptomatic, benign and often reversible, but if not con-
trolled, it may progress to non-alcoholic steatohepatitis (NASH), cirrhosis and ultimately liver
failure [2]. Therefore, metabolic perturbations contributing to the development of the disease
should be identified before clinical manifestations occur. The metabolic abnormalities related
to fatty liver are reflected in the level of circulating metabolites. Thus, comprehensive metabolic
profiling holds potential for identifying specific disease-related patterns and non-invasive bio-
markers [3]
Metabolic profiling studies have commonly noted increased free fatty acids and other lipid
species in the plasma or serum of subjects with NAFLD [4]. In particular, acylcarnitines, lyso-
phosphatidylcholines and triacylglycerol with low carbon number and double-bond content,
have emerged as auspicious liver fat biomarkers [5,6]. Recent studies have also demonstrated
increased circulating branched-chain amino acids (BCAAs) and their metabolic intermediates
in subjects with NAFLD [7–9] and NASH[9,10] compared to healthy controls, but the underly-
ing mechanisms of these associations remain to be established. These findings indicate that
metabolic profiling can provide important information about etiology of the development and
progression of NAFLD. However, the influence of extra-hepatic tissues on hepatic steatosis is
incompletely understood.
Since NAFLD is closely associated with obesity, insulin resistance and type 2 diabetes[11–
13], it is suspected that adipose tissue and skeletal muscle may play an important role in the
development of NAFLD. Indeed, growing evidence indicates that adipose tissue dysfunction
[14] and increased secretion of adipokines [15] are implicated in the systemic nature of
NAFLD pathogenesis. Experimental studies have demonstrated that skeletal muscle insulin
resistance promotes liver fat accumulation by altering the distribution pattern of postprandial
energy storage [16]. Skeletal muscle has also been shown to modulate adipose tissue metabo-
lism [17]. The newly discovered myokine, irisin, which has been proposed to convey the inter-
organ signaling between skeletal muscle and adipose tissue, has recently been associated with
NAFLD [18,19]. Furthermore, both skeletal muscle and adipose tissue are significant regulators
of systemic amino acid metabolism, as most of the catabolic activity of BCAAs resides in these
tissues [20]. Therefore, tissue-specific alterations in BCAA metabolism may contribute to the
elevated levels of circulating BCAAs associated with fatty liver [21,22].
The aim of our study was to identify early systemic metabolic alterations associated with
liver fat accumulation in healthy middle-aged men and women with and without NAFLD. In
addition, we studied global gene expression profiles of adipose tissues and skeletal muscle, the
purpose being to describe the early changes in the metabolic pathways that accompany liver fat
accumulation and relate these to the serum metabolite profiles and associated clinically rele-
vant factors.
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Materials and Methods
Study participants
This article is a part of the Calex family study (n = 282 families), which has been described else-
where [23,24]. For the purpose of this report, a subgroup of families (n = 74), comprising 222
individuals (daughter, mother and father) with no history of liver, pancreas or heart disease, or
of heavy drinking, were contacted by letters for an additional study aimed at identifying the
early metabolic alterations associated with liver fat accumulation. A total of 184 individuals
responded to our invitation, of whom 163 (53 fathers, 53 mothers and 57 daughters) attended
the laboratory tests. For this report, all the daughters were excluded owing to the low number
with NAFLD (n = 5), leaving only the mothers and fathers (n = 106). Valid measurements of
liver fat were unavailable for two men. In addition, two men reported recent alcohol consump-
tion of>21 drinks on average per week and one woman reported>14 drinks on average per
week. These individuals were therefore excluded. Hence, the final numbers of participants were
49 men and 52 women. Thirty (n = 30) participants had NAFLD, as defined by the cut-off LFC
value of>5.56% [25]. The remainder, with a LFC value of<5.56%, were assigned to the
healthy control group (n = 71). Of these 101 subjects, 32 (11 with NAFLD and 21 healthy con-
trols) agreed to donate subcutaneous and skeletal muscle (vastus lateralis) biopsies.
Health history and current status was checked by the study physician. Nomajor liver (cancer,
hepatitis), pancreas (type I/II diabetes) or cardiac diseases were found. However, five men (3 healthy
controls and 2 NAFLD) and two women (1 healthy control and 1 NAFLD) were using statins, and
thirteen men (6 healthy controls and 7 NAFLD) and four women (3 controls and 1 NAFLD) were
using hypertension medication. In addition, one man and three women were using thyroxine for
hypothyreosis. All the other subjects were clinically euthyreotic. Twenty-two women were in early
post menopause (15 healthy controls and 7 NAFLD), but there was no difference between the two
groups in menopausal age, and none of the women were on hormonal replacement therapy.
Including or excluding these women did not influence the results, and hence they were included
in the final analysis. The study protocol was approved by the ethics committee of the Central Fin-
land Health Care District. A written informed consent was obtained from all participants.
Background information, liver fat content, abdominal fat mass and
myocellular lipid assessment
Body height, weight and body mass index (BMI) were assessed and the results reported else-
where [23,26]. Dietary intake of total energy and energy-yielding nutrients were assessed from
three-day food records and analyzed using Micro-Nutrica software developed by the Social
Insurance Institution of Finland and updated with data for new foodstuffs by the study nutri-
tionist [27]. Leisure time physical activity (PA), including walking, jogging, running, gym fit-
ness, ball games, swimming, etc., expressed as hours/week and times/week, was evaluated using
a validated self-administered physical activity questionnaire, as described previously [28].
Whole body fat mass (FM) was assessed by Dual-energy X-ray absorptiometry (DXA Prod-
igy, GE Lunar Corp., Madison, WI USA). In this study, two repeated measurements of FM
showed a coefficient of variation (CV) of 2.2% [23].
Liver and abdominal regions were scanned using a 1.5 Tesla MR scanner (GE Signa CV/i,
General Electric Healthcare, Waukesha, WI, USA). LFC was assessed by 1HMRS with a PRESS
sequence and was analysed using the Linear Combination of Model spectra software which is
generally considered to be the gold standard for in-vivo spectroscopy analysis [29,30].
Abdominal adipose tissue compartments (subcutaneous = SAT, visceral = VAT, retroperi-
toneal = RAT) were quantified from a single slice image at the level of the L2-L3 intervertebral
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disc using OsiriX software (OsiriX Foundation, Geneva, Switzerland). The results were con-
verted into tissue fat mass in kg taking slice thickness into account and assuming an adipose
tissue density of 0.9196 g/ml [31].
Muscle intra-myocellular lipid (IMCL) and extra-myocellular lipid (EMCL) from the tibialis
anterior muscle were measured using a similar 1H MRS method with a surface coil placed over
the middle part of the muscle[32]. In order to obtain maximal IMCL and EMCL separation,
the tibialis anterior muscle was aligned as closely as possible with the direction of the magnetic
field and the voxel was placed parallel to the muscle fibers[32].
Biochemical assessments
Blood samples were collected in the morning between 7:00 and 9:00 am after overnight fasting.
Among the women with regular menses, the samples were collected between 2 and 5 days after
menstruation onset. Plasma glucose, serum alkaline phosphatase (ALP), alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT) and non-esteri-
fied fatty acids (NEFA) were assessed by a KONELAB 20XTi analyzer (Thermo Fischer
Scientific inc. Waltham, MA, USA). Plasma insulin was assessed by chemiluminescent immu-
noassay (Diagnostic Products Corporation, Los Angeles). The intra- and inter-assay CVs were
3.4% and 2.0% for glucose, 11% and 3.4% for insulin, and 7.4% and 8.4% for NEFA. The
HOMA-IR index (homeostatic model assessment of insulin resistance) was calculated as (fast-
ing glucose x fasting insulin/22.5). Serum leptin was assessed using human leptin (ELISA;
Diagnostic Systems Laboratories, Inc., Webster, TX). Total adiponectin was measured by an
enzyme immunoassay method using the Quantikine human total adiponectin/Acrp30 immu-
noassay (R&D Systems, Minneapolis, MN). The inter- and intra-assay coefficients of variation
(CVs) were 2.2% and 2.7% for leptin, and 3.3% and 4.3% for adiponectin. Serum high-sensitiv-
ity C-reactive protein (hsCRP) was assessed using an ELISA DuoSet (R&D Systems and Diag-
nostic Systems Laboratories, Inc). The intra- and inter-assay CVs were 4.6% and 6.9%.
Serum NMR spectroscopy
All serum samples were analyzed using a high-throughput serum NMR metabolomics plat-
form; the experimental protocols, including sample preparation and NMR spectroscopy, have
been described in detail elsewhere [33,34]. Altogether 130 metabolites were assessed.
Subcutaneous adipose tissue biopsies
Subcutaneous adipose tissue biopsies were obtained from 16 men and 16 women under local
anesthesia after an overnight fast. A region 5 cm lateral from the umbilicus either to the left
side or right side was sterilized. A small intracutaneous injection was made, and 2 ml of a local
anesthetic agent (lidocaine) was injected. After 5 min, anesthesia was confirmed. The skin was
then sterilized again and 10ml of 0.9% sodium-chloride was aspirated using a 16 G x 40 mm
needle fitted to a 50-mL syringe. Approximately two-thirds of the length of the needle was
inserted into the subcutaneous fat, and 5 ml of 0.9% sodium chloride was injected. The needle
piston was then pulled back maximally and released until it was locked by a stopper, thereby
creating a vacuum. Tissue resistance was created by gripping the abdominal skin with one
hand while the other hand rotated the needle (back and forth) throughout the tissue (by a back
and forth motion). Once the tissue had been aspirated by the syringe, the needle was with-
drawn, and the piston removed. The adipose tissue samples were washed with saline solution,
and were immediately frozen in liquid nitrogen and stored at—80°C.
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Skeletal muscle biopsies
Vastus lateralis biopsies were taken from 16 men and 16 women under local anesthesia after an
overnight fast. Biopsies were taken from the vastus lateralis dx muscle with a 5-mm Bergström
biopsy needle, midway between the patella and greater trochanter. The location and optimum
depth for the muscle biopsy were confirmed by ultrasound imaging. The skin covering the
identified location was sterilized and 4 ml of local anesthetic agent (lidocaine) was injected into
the subdermal tissue. A cooling pack was then applied to the location. After 10 minutes, anes-
thesia was confirmed, the skin was sterilized again and a small stab incision made with a surgi-
cal scalpel. Next, the biopsy needle, attached to a syringe, was introduced perpendicularly into
the incision. The piston was then pulled back maximally, creating a vacuum, and the sample
was obtained. After this, pressure was applied to the incision site to induce hemostasis. The
muscle sample was cleaned of any visible connective and adipose tissue, as well as blood, and
was frozen immediately in liquid nitrogen (−180°C) and stored at −80°C.
RNA extraction
Total RNA was extracted from the biopsies using the FastPrep system (MP Biomedicals,
France) and a RNeasy Lipid Tissue Mini Kit (QIAGEN, Gaithersburg, MD, USA) according to
manufacturer’s instructions. Total RNA was digested on column with a RNase-free DNase set
(QIAGEN) during RNA isolation. The quality of the total RNA was studied using a 2100 Bioa-
nalyzer (Agilent, Santa Clara, CA, USA) and Experion Automated Electrophoresis Station
(BioRad, Hercules, CA, USA). The total RNA was amplified and processed using a Gene Chip
3´ IVT Express Kit (Affymetrix, Santa Clara, CA, USA) and hybridized on Affymetrix Human
Genome U219 Array Plates. The samples of this study have been submitted to ArrayExpress.
Protein extraction andWestern blot from skeletal muscle biopsies
The muscle biopsies were homogenized in ice-cold lysis buffer [20 mMHEPES (pH 7.4), 1 mM
EDTA, 5 mM EGTA, 10 mMMg2Cl, 100 mM β-glycerophosphate, 1 mMNa3VO4, 1 mM
DTT, 1% Triton-X-100], supplemented with protease and phosphatase inhibitors inhibitors
(Sigma Aldrich, St Louis, MO, USA).
Fifty to sixty micrograms of muscle lysate samples were separated by SDS-Page using
4–20% gradient gels on a Criterion electrophoresis cell (Bio-Rad Laboratories, Richmond, CA).
Proteins were transferred to nitrocellulose membranes at 300-mA constant current on ice at
4°C. Membranes were blocked in TBS containing 5% nonfat dry milk for 1 hour at room tem-
perature (RT), and then probed overnight at 4°C with commercially available primary antibod-
ies. All antibodies were diluted 1:1000 (except anti-GAPDH (housekeeping, which was diluted
1:40,000) in TBS containing 5% nonfat dry milk. Membranes were then washed with TBS con-
taining 0.1% Tween-20 (TBS-T) followed by 1 hour incubation with the secondary antibody.
Blots were visualized and quantified using an Odyssey CLX Infrared Imager of (Li-COR Biosci-
ences) and the manufacturer's software. When re-probing was needed, the membranes were
incubated in 0.2 M NaOH for 10 min at RT, washed with TBS and re-probed with appropriate
antibodies. All samples were run in the same gel to minimize variability and the quantitative
results for each protein were normalized to GAPDH.
Transcriptomics analysis
Analysis of the transcriptomics data have been reported earlier [1]. Briefly, the gene values of
the expression measurements were analyzed by using the Robust Multiarray Averaging (RMA)
algorithm, as implemented in the R package affy. We ran the differentially expressed genes
Adipose Tissue, Metabolomics and Non-Alcoholic Fatty Liver Disease
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(DEG) analysis with the LimmaR package utilizing linear modeling and empirical Bayes meth-
ods. Raw p-values were adjusted using the Benjamini and Hochberg multiple adjustment
method.
Quantitative PCR
The results of the adipose tissue microarray analyses were confirmed by qPCR as described ear-
lier [1]. Briefly, qPCR was performed on MMP9 and VAV1 from the same RNA samples. A
High Capacity cDNA Synthesis Kit (Applied Biosystems, Foster City, CA, USA) was used to
reverse transcribe 230 ng of RNA. Real-time PCR analysis was performed using iQ SYBR
Supermix and CFX96™ Real-time PCR Detection System (Bio-Rad Laboratories, Richmond,
CA, USA).
The primer sequences were as follows:
MMP9 sense: 50-GAGTGGCAGGGGGAAGATGC-30, and antisense 50-CCTCAGGG
CACTGCAGGATG-30
VAV1 sense: 50-AGCAGTGGGAAGCACAAAGTATT-30, and antisense 50-GTCAC
GGGCGCAGAAGTC-30
GAPDH sense: 50-CCACCCATGGCAAATTCC-30 and antisense: 50-TGGGATTTCCAT
TGATGACAA- 30
Relative expression levels for MMP9 and VAV1 were calculated with the DDCt method and
normalized to the expression of GAPDH. The fold changes in each gene between the groups
were similar to those detected in the microarray analysis (data not shown).
Gene enrichment analysis
The enriched Gene Ontology (GO) terms or Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways for a given gene set were calculated by utilizing the R packages GOStats [2].
In the enrichment analysis, all the human ENSEMBL genes were used as a background gene
group. Categories with a p-value lower than 0.05 are considered significantly enriched. We
detected the genes whose expression was related to liver fat content by utilizing the following
two criteria: 1) the DEG analysis with an adjusted p-value of<0.05 identified genes that were
differentially expressed in the healthy control and NAFLD groups, and 2) the genes had a fold
change of> 1 in the NAFLD group compared to the healthy controls. The mean-centroid
value representing the “activity” of the regulated part of the pathway was computed by normal-
izing the expression levels of all the genes in the subset to a mean of zero across all individuals.
Mean centroids have previously been shown to correlate with various metabolic and physio-
logic parameters [22,35], and may therefore be used to assess gene expression patterns that are
associated with metabolic diseases. Correlation analyses with liver fat and serum metabolites
were performed as described the next section.
Statistical methods
Continuous data were checked for normality by Shapiro-Wilk’s test before each analysis using
PASW statistics version 21 (IBM Corporation, USA). If data were not normally distributed,
their natural logarithms were used. Since the data were from a family study, shared environ-
mental (household) similarity was controlled for in the analysis. The linear mixed model was
used to compare levels of the outcome variables between the NAFLD and healthy control
groups. Contrast tests were used in mixed models to assess the effect of gender while control-
ling for dependency among family members with random effects.
The metabolomics data were clustered utilizing a hierarchical clustering algorithm which
has been reported elsewhere [34]. The results are expressed as means with standard deviation
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(SD). P-values were adjusted to control for the false discovery rate (FDR) using the method of
Benjamini and Hochberg when comparing metabolites between the healthy control and
NAFLD groups [36]. To identify relevant metabolites associated with LFC, we used principal
component analysis to reduce a large number of correlated variables to fewer uncorrelated fac-
tors. Metabolite factor scores were calculated for each individual based on the constructed scor-
ing coefficients. The principal component score is a transformation on the values of the
metabolites, which can be considered as a weighted measure of the variability shared by the
variables. Fasting levels of amino acids, fatty acids, phospholipids, glycoproteins, ketone bodies,
and glycolysis and gluconeogenesis intermediates were included in the principal component
analysis. Mean metabolite factor levels were compared between the NAFLD and healthy con-
trol groups. To exclude the possibility of misclassification, we divided the participants into
quintiles based on liver fat content and compared their mean metabolite factor levels adjusting
for HOMA-IR, BMI and visceral fat mass. Pearson correlation analyses were performed to
determine the relationship between the gene pathways and clinical characteristics. Statistical
significance was set at p< 0.05.
Results
Anthropometry, fat depots, lifestyle factors and conventional serum
biomarkers
The mean liver fat content in the NAFLD and healthy control groups were 13.6% vs. 1.9%
(p<0.001). No group by gender interaction was observed in liver fat content. The NAFLD par-
ticipants were heavier and had higher BMI, total, visceral and retroperitoneal FM and IMCL
compared to the healthy controls (p0.005 for all, Table 1). The NAFLD participants had
higher fasting glucose, insulin, HOMA-IR, triglycerides, hsCRP, NEFA, leptin and liver
enzymes but lower adiponectin and HDL-C levels than the healthy controls. (p<0.05 for all,
Table 1). No differences were found in physical activity, dietary energy or energy yield nutrient
intakes between the NAFLD and healthy control groups.
Serummetabolites
A cluster analysis of serum metabolites is illustrated in S1 Fig. The analysis revealed increased
levels of very-low density lipoprotein (VLDL) subclasses, mono-unsaturated fatty acids, gluco-
neogenic substrates, orosomucoid and branched-chain amino acids, and decreased levels of
high-density lipoprotein subclasses in participants with NAFLD. All essayed metabolites and
lipoprotein subclass quantities and statistics are shown in S1 Table.
To further identify relevant metabolites associated with NAFLD, we used principal compo-
nent analysis. Mean metabolite component levels are shown in Table 2. Factor 1 (omega 7and 9
and saturated fatty acids, total fatty acids and mono-unsaturated fatty acids), factor 2 (isoleucine,
leucine, valine, phenylalanine, tyrosine and orosomucoid) and factor 3 (acetate, alanine, lactate,
pyruvate) were significantly higher in the NAFLD group compared to the healthy control group
(p = 0.008 to p<0.001). No group by gender interaction was found in any of the factors.
The mean metabolite component levels were further compared between the quintiles of
liver fat content adjusting for gender, BMI, visceral fat mass, leptin and adiponectin (S2
Table). Factor 1 was significantly higher in the 5th quintile compared to the 1st and 2nd quin-
tiles. Factor 2 was significantly higher in the 3rd, 4th and 5th quintile compared to the 1st quin-
tile, and factor 4 was significantly higher in the 5th quintile compared to 1st quintile. No
significant difference in the other factors was observed between the highest and lowest quintile
groups.
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Adipose tissue gene expression
To elucidate the metabolic pathways associated with NAFLD, we studied global transcript pro-
files of adipose tissue and skeletal muscle. Microarray analysis revealed 709 differential
Table 1. Physical characteristics, fat mass distribution, glucosemetabolism hormones and liver enzymes in the healthy controls and NAFLD
group (MIXEDmodel estimatedmarginal means with 95% confidence intervals are given taking into account shared environment within family
(husband and wife) and contrast estimates’ p-values were used to localize the significant differences between the two groups and group by gender
interaction).
Healthy controls (n = 71) NAFLD (n = 30)
Mean 95% CI Mean 95% CI p Group by gender
Men/women (n) 31/40 18/12 0.372
Age (years) 51.7 (50.5, 52.9) 52.9 (50.9, 54.8) 0.244 0.479
Height (cm) 171.4 (170.1, 172.8) 171.6 (169.5, 173.8) 0.480 0.382
Weight (kg) 73.2 (70.7, 75.7) 87.3 (83.3, 91.3) <0.001 0.493
BMI 24.9 (24.0, 25.7) 29.6 (28.3, 30.9) <0.001 0.516
FM (kg) 19.8 (18.0, 21.6) 30.8 (27.9, 33.8) <0.001 0.209
SAT (kg) 2.82 (2.49, 3.15) 4.61 (4.08, 5.15) <0.001 0.002
VAT (kg) 0.749 (0.679, 0.818) 1.1 (0.99, 1.21) 0.005 0.293
RAT (kg) 1.13 (0.978, 1.28) 2.2 (2.00, 2.44) <0.001 0.470
IMCL (%) 0.16 (0.142, 0.179) 0.24 (0.212, 0.268) 0.001 0.780
EMCL (%) 0.345 (0.281, 0.409) 0.408 (0.300, 0.515) 0.139 0.216
Energy (kcal/day) 1979 (1963, 2095) 1958 (1759, 2157) 0.674 0.947
Protein (E%) 18.1 (17.4, 18.8) 18.8 (17.5, 20.0) 0.557 0.980
Fattot (E%) 33.5 (31.8, 35.2) 31.7 (28.7, 34.5) 0.256 0.509
SAFA (E%) 12.9 (12.1, 13.7) 12.5 (11.1, 13.8) 0.588 0.766
MUFA (E%) 11.4 (10.6, 12.3) 10.4 (8.96, 11.9) 0.300 0.618
PUFA (E%) 6.00 (5.53, 6.45) 5.43 (4.63, 6.23) 0.100 0.170
Ch (E%) 45.8 (43.9, 47.7) 47.2 (43.9, 50.5) 0.359 0.484
Sucrose (E%) 5.02 (4.09, 5.95) 6.72 (5.12, 8.31) 0.515 0.419
PA (time/week) 2.94 (2.53, 3.35) 2.2 (1.55, 2.86) 0.143 0.806
PA (hour/week) 3.81 (3.36, 4.26) 3.25 (2.54, 3.97) 0.183 0.525
Glucose (mmol/l) 5.46 (5.33, 5.59) 5.71 (5.49, 5.92) 0.030 0.239
Insulin (μIU/ml) 6.22 (5.12, 7.32) 10.3 (8.58, 12.1) 0.001 0.306
HOMA-IR 1.53 (1.24, 1.82) 2.68 (2.21, 3.15) <0.001 0.215
hsCRP (ng/ml) 722 (376, 1068) 1562 (1020, 2103) 0.006 0.709
NEFA (μmol/l) 395 (353, 438) 453 (383, 524) 0.032 0.069
Serum-TG 1.03 (0.93, 1.12) 1.45 (1.30, 1.59) <0.001 0.067
Leptin (ng/ml) 11.9 (7.8, 16.0) 30.9 (24.8, 37.0) <0.001 0.001
Adiponectin (μg/ml) 9.4 (7.8, 11.0) 5.1 (2.6, 7.6) 0.011 0.103
ALP (IU/l) 60.5 (56.9, 64.1) 64.9 (58.9, 70.9) 0.299 0.771
ALT (IU/l) 18.9 (16.0, 21.8) 30.9 (26.3, 35.5) <0.001 0.129
AST (IU/l) 20.1 (18.6, 21.7) 23.0 (20.6, 24.4) 0.003 0.020
GGT (IU/l) 29.6 (25.0, 34.2) 39.4 (32.0, 46.8) 0.009 0.103
NAFLD = non-alcohol fatty liver disease; BMI = body mass index; FM = fat mass of the whole body; SAT = abdominal subcutaneous adipose tissue;
VAT = visceral adipose tissue; RAT = retroperitoneal adipose tissue; IMCL = intra-myocellular lipids; EMCL = extra-myocellular lipids; E = energy;
SAFA = saturated fatty acids; MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fatty acids; Ch = carbohydrate; PA = physical activity;
hsCRP = high-sensitivity C-reactive protein; NEFA = non-esteriﬁed fatty acids; TG = triglycerides; ALP = alkaline phosphatase; ALT = alanine
aminotransferase; AST = aspartate aminotransferase; GGT = γ-glutamyltransferase.
doi:10.1371/journal.pone.0138889.t001
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expressed genes (adjusted p<0.05) in the adipose tissue of the NAFLD group. Of these 709
genes, 255 were up-regulated and 454 were down-regulated (S3 Table). Kyoto Encyclopedia of
Genes and Genomes (KEGG) enrichment analysis of the differentially expressed genes
(p< 0.05) identified 6 down regulated pathways (Table 3). The most down-regulated pathway
was valine, leucine and isoleucine degradation (p = 4.6x10-9). Down-regulated genes in this
pathway included the mitochondrial components (BCKDHB and DLD) that are common to
the degradation of all BCAAs, i.e., isoleucine, leucine and valine. Genes specific for the degra-
dation of leucine (AUH), isoleucine (PCCA and PCCB) and valine (HIBADH) were also
down-regulated in the subjects with NAFLD.
The mean centroid of the BCAA degradation pathway correlated negatively with liver fat
content and serum metabolite factor 2 (Fig 1), serum total BCAA (r = -0.471, p = 0.023) and
fasting insulin concentrations (r = -0.550, p = 0.008) and HOMA-IR (r = -0.542, p = 0.009). In
a multiple linear regression analysis, including total FM, visceral FM, retroperitoneal FM,
HOMA-IR and hsCRP, only the BCAA degradation pathway and serum metabolite factor 2
Table 2. Meanmetabolite component levels stratified by the healthy control and NAFLD groups (MIXEDmodel estimated marginal means with
95% confidence intervals are given taking into account shared environment within family, and contrast estimates’ p-values were used to localize
the significant differences between the two groups and group by gender interaction).
Healthy Controls (n = 71) NAFLD (n = 30)
Mean 95% CI Mean 95% CI p Group by Gender
Factor 1 -0.233 (-0.471, 0.006) 0.640 (0.268, 1.011) <0.001 0.171
Factor 2 -0.235 (-0.450, -0.019) 0.610 (0.277, 0.943) 0.001 0.450
Factor 3 -0.216 (-0.463, 0.031) 0.492 (0.111, 0.874) 0.008 0.368
Factor 4 -0.049 (-0.303, 0.204) -0.051 (-0.446, 0.343) 0.996 0.988
Factor 5 0.015 (-0.260, 0.290) -0.054 (-0.479, 0.371) 0.938 0.879
Factor 6 0.093 (-0.179, 0.365) -0.173 (-0.593, 0.248) 0.753 0.558
NAFLD = non-alcohol fatty liver disease; values are given as mean and 95% conﬁdent interval (CI). Factor 1 (Omega 7 and 9 and saturated fatty acids,
total fatty acids, mono-unsaturated fatty acids); Factor 2 (isoleucine, leucine, valine, phenylalanine, tyrosine and orosomucoid); Factor 3 (acetate, alanine,
lactate, pyruvate); Factor 4 (esteriﬁed cholesterol, free cholesterol, omega 6 fatty acids, phosphoglycerides, phosphocholines and sphingomyelines);
Factor 5 (beta-hydroxybutyrate, citrate, histidine); Factor 6 (acetoacetate, glutamine)
doi:10.1371/journal.pone.0138889.t002
Table 3. KEGG pathway enrichment analysis of differentially expressed genes in adipose tissue.
P-value Count Size Pathway name Genes
4.6x10-9 18 44 Valine, leucine and isoleucine
degradation
ACADM, ACADSB, ALDH7A1, ALDH9A1, AUH, BCKDHB, DLD, HADH, HADHA,
HADHB, HIBADH, HIBCH, MCCC1, MCEE, MUT, OXCT1, PCCA, PCCB
3.0x10-7 13 30 Citrate cycle (TCA cycle) CS, DLD, DLST, FH, IDH1, IDH3A, IDH3B, PCK1, PDHB, SDHB, SUCLA2, SUCLG1,
SUCLG2
3.3x10-5 13 43 Fatty acid degradation ACADM, ACADSB, ACADVL, ACSL1, ADH1B, ADH5, ALDH7A1, ALDH9A1, DCI,
HADH, HADHA, HADHB, PECI
7.1x10-3 20 132 Oxidative phosphorylation ATP5A1, ATP5B, ATP5G3, ATP5L, ATP6AP1, ATP6V1C1, COX5A, COX5B, CYC1,
NDUFA10, NDUFA12, NDUFA6, NDUFB4, NDUFB5, NDUFB6, NDUFS1, NDUFS2,
NDUFS4, SDHB, UQCRC2
1.9x10-2 11 65 Glycolysis / Gluconeogenesis ADH1B, ADH5, ALDH7A1, ALDH9A1, DLD, ENO1, PCK1, PDHB, PFKP, PGK1, PGM1
3.5x10-2 12 80 Glycerophospholipid metabolism AGPAT6, AGPAT9, CEPT1, CHKA, CHPT1, CRLS1, ETNK2, GNPAT, GPD1L, GPD2,
LPCAT1, PGS1
Count = Amount of differentially expressed genes that mapped on pathway. Size = Total amount of genes involved in pathway.
doi:10.1371/journal.pone.0138889.t003
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remained significantly associated with liver fat (β = -0.791, and β = 0.992, respectively, p<0.05
for both). Non-alcoholic fatty liver was also associated with significant down-regulation of the
energy metabolism in the adipose tissue. Fatty acid degradation, citric acid cycle and oxidative
phosphorylation were associated with liver fat (r values ranged from -0.684 to -0.767, p<0.001
for all, Fig 2). No significant associations were found between the gene pathways and other
serum metabolite factors (data not shown).
Skeletal muscle gene expression and signaling protein phosphorylation
Unexpectedly, no differentially expressed genes were found in the skeletal muscle. However,
since skeletal muscle is the primary site of insulin-stimulated glucose disposal, we further stud-
ied whether there were differences in the phosphorylation levels of several signaling proteins
related to glucose metabolism. No differences in the phosphorylation levels of insulin receptor
Fig 1. Correlations between liver fat content (LFC) assessed by 1H MRS and different adipose tissue gene expression clusters in certain pathways.
The LFC was transformed into a normal distribution by natural logarithms. Each dot represents an individual and the line is a linear regression fit line.
doi:10.1371/journal.pone.0138889.g001
Fig 2. Correlations between serummetabolites factor 2 (isoleucine, leucine, valine, phenylalanine, tyrosine and orosomucoid) and different
adipose tissue gene expression clusters in certain pathways. Each dot represents an individual and the line is a linear regression fit line.
doi:10.1371/journal.pone.0138889.g002
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β and its downstream targets of Akt, ERK1/2, or mTOR and 4EBP1 were found. The level of
phosphorylated AS160, which promotes translocation of glucose transporters to the cell mem-
brane, was also similar between the groups.
Discussion
In this study, we showed that increased serum branched-chain and aromatic amino acids are
already present well-below the clinical cutoff value for NAFLD. In addition, reduced BCAA
catabolism and mitochondrial energy metabolism were observed in the adipose tissue of the
NAFLD group, whereas no significant between-group differences in skeletal muscle gene
expression were found.
The pathophysiology of NAFLD is complex and has not been fully elucidated. However,
there is growing evidence that obesity is an important factor in its causation [37]. Recent stud-
ies suggest that the major basis for this link is the ability of obesity to engender insulin resis-
tance [12]. The current theory suggests that as the adipose tissue mass expands, chronic
inflammation in the adipose tissue ensues [38]. The inflamed adipose tissue becomes insulin
resistant, and the impaired ability of insulin to suppress lipolysis leads to increased flux of non-
esterified fatty acids, which accumulate in the liver as triglycerides [39]. The excessive accumu-
lation of intrahepatic triglycerides gradually attenuates the ability of insulin to suppress hepatic
gluconeogenesis and triglyceride synthesis, resulting in the development of hyperglycemia,
hyperinsulinemia and dyslipidemia [40]. However, studies have suggested that NAFLD can
also develop in the absence of marked insulin resistance and increased adipose tissue lipolysis
[41], and that hepatokines may be involved in the cross-talk between liver and extra-hepatic
tissues [42]. The results of the present study showed that all the measures of adiposity, serum
glucose, insulin and HOMA-IR as well as free fatty acids, triglycerides and CRP were higher in
the NAFLD group compared to healthy controls. Elevated concentrations of gluconeogenetic
substrates, VLDL triglycerides and various species of fatty acids further supported the notion
of increased gluconeogenetic activity and imbalanced lipid metabolism in the subjects with
NAFLD.
Significant increases in serum BCAA and aromatic amino acid concentrations were found
in the subjects with NAFLD compared to those with low liver fat content. These findings dem-
onstrate the perturbations in systemic amino acid homeostasis that accompany liver fat accre-
tion. Recent studies have also shown increased serum BCAA in subjects with NAFLD [7,9,43].
However, these studies were conducted in morbidly obese patients undergoing bariatric sur-
gery [9], or in subjects with type 2 diabetes using non-specific ultrasonography [7], which is
substantially limited by its low sensitivity to mild steatosis and inability to provide reliable
quantitative information on liver fat infiltration [43]. Another study found increased BCAA in
the plasma of subjects with NASH but not NAFLD when compared to healthy controls [44].
However, no significant difference in BCAA was found between NAFLD and NASH, which is
not surprising given that steatosis and steatohepatitis are defects on a continuum. Furthermore,
although biopsy is considered the “golden standard” in comparative studies of fatty liver dis-
ease, sampling errors have been shown to limit its diagnostic accuracy [45]. Thus, one should
bear in mind the possibility of methodological errors when interpreting dichotomized data,
especially when the variable under investigation is a continuous variable such as liver fat [46].
Here, we used 1H magnetic resonance spectroscopy, which provides a highly specific estima-
tion of hepatic fat in vivo [30]. To overcome the possibility of misclassification, we also divided
our participants into quintile groups based on liver fat content. The results showed that the
level of the metabolite factor consisting of BCAA and aromatic amino acids was significantly
elevated at mean liver fat content of 2.4% (S2 Table), which is well below the clinical diagnostic
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cut-off value. This finding suggests that clinically meaningful hepatic steatosis could be present
even at less than 5% liver fat content. Importantly, we have previously demonstrated with
another study cohort that the same metabolites as in metabolite factor 2 (BCAA and tyrosine
and phenylalanine) were auspicious biomarkers determining metabolic health independent of
obesity and physical activity [34]. Other studies have also reported associations between sys-
temic BCAA and metabolic health [47–49]. Although we cannot fully explain the discrepancy
between our study and the other studies in te the state and progression of NAFLD, our results
suggest that perturbations in systemic BCAA homeostasis could be an early event in the devel-
opment of NAFLD. This notion is supported by a recent study which demonstrated that
chronic elevation of circulating BCAA induces hepatic mitochondrial dysfunction in NAFLD
[50].
We further searched for signs of early changes in metabolic pathways in the adipose tissue
and skeletal muscle. We found a significant reduction in the adipose tissue BCAA catabolism
pathway in subjects with NAFLD compared to those with low liver fat content. The decrease in
BCAA catabolism was inversely associated with the serum total BCAA, serummetabolite factor
2, fasting insulin, HOMA-IR and liver fat content. These findings are in line with an earlier
study in monozygotic twins discordant for obesity, which showed that down-regulation of
BCAA catabolism in subcutaneous adipose tissue was associated with increased insulin resis-
tance and liver fat content [22]. In our study, liver fat accumulation was also associated with
significant down-regulation of the energy metabolism in the adipose tissue. Thus it is possible
that decreased BCAA catabolism and impaired mitochondrial function in subcutaneous adi-
pose tissue could link excess adiposity to the development of insulin resistance and liver fat
accumulation [51].
The down-regulation of BCAA catabolism in the present study could be ascribed to reduced
mitochondrial respiration, as indicated by the concurrent significant down-regulation of the
TCA cycle, oxidative phosphorylation and decreased fatty acid degradation in the adipose tis-
sue. These metabolic impairments could also be attributable to local inflammation induced by
excessive enlargement of adipocytes or diminished adipocyte differentiation [52]. A study with
monozygotic twins showed marked inflammation in the subcutaneous adipose tissue concur-
rently with decreased BCAA catabolism in obese subjects [22]. Inflammation-induced regula-
tion of BCAAmetabolism in visceral, but not subcutaneous adipose tissue was also recently
reported [53]. In the present study, inflammatory pathways were not significantly up-regulated
in the adipose tissue of the participants with NAFLD. However, the two most over-expressed
genes in the adipose tissue were chitinase-3-like protein 1 (CHI3L1) and matrix metallopepti-
dase 9 (MMP9) (S3 Table). These genes are related to cytoskeleton re-organization and degra-
dation of the extracellular matrix and have been suggested to cause inflammatory cell
infiltration, resulting in persistent inflammation in the adipose tissue [54]. These results are
consistent with the higher serum hsCRP and orosomucoid observed in subjects with NAFLD,
indicating the presence of subclinical low grade inflammation.
In addition to adipose tissue dysfunction, recent studies have implicated increased intra-
myocellular lipid content [55], increased muscle insulin resistance [16] and impaired skeletal
muscle energy metabolism [56] in hepatic steatosis. In the present study, significantly higher
intramuscular lipid content was observed in the NAFLD group compared to the low liver fat
content group. Unexpectedly, no difference between the groups in gene expression profiles in
the skeletal muscle was found. To confirm these findings with respect to glucose metabolism,
we further studied whether there were differences in the phosphorylation levels of several sig-
naling proteins. No significant differences in the phosphorylation levels of insulin receptor β
and its downstream targets of Akt, ERK1/2, or mTOR and 4EBP1 were found. Nor was there
any difference in the level of phosphorylated AS160, which promotes translocation of glucose
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transporters to the cell membrane. These findings by no means negate the role of skeletal mus-
cle insulin resistance in the development of systemic metabolic disorders. However, these find-
ings do suggest that, at least in the fasting state, skeletal muscle glucose metabolism is not
altered in the early stages of NAFLD, irrespective of increased intra-myocellular lipid content.
Our study is not without limitations. We acknowledge that our approach cannot determine
causality and that the results can indicate only a general pattern. The study was conducted dur-
ing 2009 to 2010. The interval between the different data collection points for each study par-
ticipant varied to some extent, ranging from a few days to several months. However, there was
no difference between the healthy control and NAFLD groups in the sampling time window.
Further, no change in body weight or body composition was observed during the study period,
nor was there any change in diet. The study participants were married couples drawn from a
comprehensive and carefully performed family study. The couples shared the same family envi-
ronment and living conditions. They were carefully selected in order to minimize confounding
factors. For these reasons, we are confident that our results are not biased by background char-
acteristics and health history. However, the narrow age range of the subjects in our study (50–
55 years) may partly explain the lack of agreement between some of our findings and data from
previous studies, and thus suggest that our results should be interpreted in the context of age. It
should also be noted that this study is limited by the fact that adipose tissue and skeletal muscle
biopsies were only available for a relatively small group of subjects (11 with and 21 without
NAFLD). However, we used the state-of-the-art method 1HMRS to quantify the ectopic fat
content and serum metabolites. Furthermore, all the NAFLD subjects were in early or in mod-
erate stage of fatty liver, which gave us the possibility to identify biomarkers associated with
NAFLD in its early stage.
In summary, we demonstrate that already in its early stage liver fat accumulation is associ-
ated with increased serum branched-chain and aromatic amino acids. Significant down-regula-
tion of BCAA catabolism and mitochondrial energy metabolism in the adipose tissue was
found in participants with NAFLD, whereas no aberrant gene expression in skeletal muscle
was observed. The observed associations between decreased BCAA catabolic activity and
serum metabolite factor 2, total BCAA concentration and liver fat content suggest that adipose
tissue dysfunction may play a key role in the systemic nature of NAFLD pathogenesis. How-
ever, whether BCAAs are involved in the development of NAFLD in a functional manner is
unclear and warrants further study.
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